CJ Group is liquidating its Netherlands-based CDMO subsidiary **Batavia Biosciences**, a cell and gene therapy contract development unit where it invested **300 billion won**. The company also halts clinical trials for its key immuno-oncology drug, marking a strategic shift away from its dual-track bio and pharmaceutical growth plan.
Menzo Havenga leads **Batavia Biosciences** as President & CEO, driving innovation in biopharmaceuticals. He focuses on overcoming challenges in vaccine development and scaling production for critical therapies. Havenga’s approach emphasizes pushing industry boundaries to deliver impactful solutions in life-saving treatments.
Batavia Biomanufacturing has opened a new commercial-scale manufacturing facility in Leiden. The site specializes in producing viral vector and viral vaccine therapeutics. Operations at the facility are set to begin in the first half of 2025.
Batavia Biosciences announces plans to build a new facility to enter commercial manufacturing. The move positions the company to scale production for biopharmaceutical products.
CJ Cheiljedang acquires Batavia, a contract development and manufacturing organization (CDMO), for $226 million. The deal expands CJ Cheiljedang’s operations into the biopharmaceutical manufacturing sector. Batavia specializes in supporting drug development and production for biotech and pharmaceutical companies.
South Korea’s CJ Cheiljedang Corp. acquires Dutch biotech firm Batavia in a deal valued at **195 million euros**. The move aligns with CJ Group’s broader expansion strategy, as Chairman Lee Jay-hyun outlines a **10 trillion won ($8.5 billion) mid-term growth plan** for the conglomerate. Batavia’s biotech assets may support CJ’s diversification beyond food and entertainment into life sciences. The acquisition reflects CJ Group’s push into high-growth sectors amid shifting global market priorities.
Batavia Biosciences, led by CEO Menzo Havenga, collaborates with Leiden Bio Science Park (LBSP) to accelerate patient-focused drug development. The Clinical Development Board ensures research outcomes translate into high-value medical products. Batavia Biosciences leverages LBSP’s infrastructure to bridge academic discoveries and clinical applications.